Hang Nielsen

Dr. Hang Nielsen


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2024 in Biomolecules
Verified
Journal Article
Open access
PDF file
HNHang Nielsen
Hang Nielsen
RHRikke Holm
Rikke Holm
RSRyan Sweazey
Ryan Sweazey
JAJens Peter Andersen
Jens Peter Andersen
PAPablo Artigas
Pablo Artigas
BVBente Vilsen
Bente Vilsen
Na+,K+-ATPase actively extrudes three cytoplasmic Na+ ions in exchange for two extracellular K+ ions for each ATP hydrolyzed. The atomic structure with bound Na+ identifies three Na+ sites, named I, II, and III. It has been proposed that site III is the first to be occupied and site II last, when Na+ binds from the cytoplasmic side. It is usually assumed that the occupation of all three Na+ sites is obligatory for the activation of phosphoryl transfer from ATP. To obtain more insight into the individual roles of the ion-binding sites, we have analyzed a series of seven mutants with substitution of the critical ion-binding residue Ser777, which is a shared ligand between Na+ sites I and III. Surprisingly, mutants with large and bulky substituents expected to prevent or profoundly disturb Na+ access to sites I and III retain the ability to form a phosphoenzyme from ATP, even with increased apparent Na+ affinity. This indicates that Na+ binding solely at site II is sufficient to promote phosphorylation. These mutations appear to lock the membrane sector into an E1-like configuration, allowing Na+ but not K+ to bind at site II, while the cytoplasmic sector undergoes conformational changes uncoupled from the membrane sector.

Verified
Journal Article
Open access
PDF file
RHRikke Holm
Rikke Holm
MTMads Schak Toustrup-Jensen
Mads Schak Toustrup-Jensen
HNHang Nielsen
Hang Nielsen
JAJens Peter Andersen
Jens Peter Andersen
BVBente Vilsen
Bente Vilsen
Serious neurological disorders are caused by mutation of Na+,K+-ATPase α1–α3 isoforms. Several disease mutations reduce the affinity for Na+, which in vivo results in an increase in the intracellular Na+ concentration with a secondary rise in intracellular Ca2+. Current treatments are ineffective, as they do not address Na+,K+-ATPase function. Hence, a platform for the development of a rational therapeutic approach that restores Na+ affinity is needed. Using the COS-1 cell expression system, one of the most conspicuous reductions in Na+ affinity of Na+,K+-ATPase has been reported for the neurological disease mutation α3-D923N of the α3 isoform. We describe here second-site mutations (“rescue mutations”) that fully restore Na+ affinity of α3-D923N and the corresponding rat α1-D928N and reveal the underlying molecular mechanism. Paradoxically, this insight evolved from investigation of a rapid-onset ataxia Na+,K+-ATPase mutant, α3-G316S, that exhibits an increased affinity for Na+. When applied as second-site mutations, α3-G316S and the corresponding rat α1-G321S are super-efficient rescuers of the reduced Na+ affinity of α3-D923N and rat α1-D928N. Replacement of the glycine with serine leads to a clash between transmembrane helices in the K+-bound E2 state of Na+,K+-ATPase but not in the Na+-bound E1 state. A similarly strong rescuing power is observed for second-site mutations breaking a salt bridge present only in the E2 state. The rescue is due to a structural change resembling the rearrangement of the ion binding sites occurring during the normal Na+,K+-ATPase transport cycle as part of the E2-to-E1 conformational transition.